Special Issue

Revolutionizing Cancer Therapy: Unleashing the Power of MET Inhibitors

Message from the Guest Editor

We would like to discuss the HGF-MET signaling pathway, which involves the interaction between the Mesenchymal Epithelial Transition Factor (MET) receptor and its ligand, the Hepatocyte Growth Factor (HGF). This pathway plays a crucial role in various cellular processes, such as cell proliferation, motility, morphogenesis, angiogenesis, and tissue regeneration. Dysregulation of the MET signaling system is associated with various malignancies. In this Special Issue, we aim to focus on the promising target agent, MET inhibitors, and invite contributions from multidisciplinary expert groups engaged in research related to targeting the MET-HGF signaling pathway for various cancer treatments. This Special Issue seeks to present studies that apply next-generation sequencing (NGS) technology to the development of target agents, not only contributing to the treatment of lung cancer, but also exploring the potential for diverse cancer types, including gastric cancer, hepatocellular carcinoma, and pancreatic cancer. We invite researchers and experts to submit their original research, reviews for consideration in this Special Issue

Guest Editor

Prof. Dr. Sang Hyub Lee

Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Republic of Korea

Deadline for manuscript submissions

closed (30 April 2024)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/181222

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)